Carisma Therapeutics Rings the Nasdaq Stock Market Closing Bell
Carisma Therapeutics (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, visits the Nasdaq MarketSite in Times Square to commemorate the recent completion of their merger with Sesen Bio and addition to Nasdaq. In honor of the occasion, Steven Kelly, President and Chief Executive Officer of Carisma, rings the Closing Bell.